A pilot study of the effect of the glycosaminoglycan sulodexide on microalbuminuria in type I diabetic patients

Current Medical Research and Opinion

Volumn 13, Issue 9, 1997, Pages 539-545

  Szelanowska, M ^a   Poplawska, A ^a   Jopdska, J ^a   Kinalska, I ^a   Grimaldi, M ^b  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b Alfa Wassermann SpA   (Italy)

Author keywords

Diabetes; Glycosaminoglycans; Nephropathy; Sulodexide; Urinary albumin excretion

Indexed keywords

ALBUMIN; GLYCOSAMINOGLYCAN; SULODEXIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INTRAMUSCULAR DRUG ADMINISTRATION; KIDNEY DISEASE; MALE; MICROALBUMINURIA;

EID: 0031005065     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007999709113327     Document Type: Article

References (23)

1. Ballard, D. J., Humphrey, L. L., Melton, L. J., et al., (1988). Epidemiology of persistent proteinuria in type II diabetes mellitus: population-based study in Rochester, Minnesota. Diabetes, 37, 405-412.
2. Ceriello, A., Quatraro, A., Ettorre, M., et al., (1993). Glucosaminoglycans administration decreases high fibrinogen plasma levels in diabetic patients. Diab. Nutr. Metab., 6, 1-4.
3. Ceriello, A., Quatraro, A., Marchi, E., et al., (1993). Impaired fibrinolytic response to increased thrombin activation in Type I diabetes mellitus: effects of the glycosaminoglycan sulodexide. Diab. Mètab., 19, 225-229.
4. Gambaro, G., and Baggio, B., (1992). Role of glycosaminoglycans in diabetic nephropathy. Acta Diabetol., 29, 149-155.
5. Gambaro, G., Cavazzana, A., Luzi, P., et al., (1992). Glycosaminoglycans prevent morphological renal alterations and albuminuria in diabetic rats. Kidney Int., 42, 285-291.
6. Gambaro, G, Venturini, A. P., Noonan, D. M., et al., (1994). Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy. Kidney Int., 46, 797-806.
7. Giorgi Pierfranceschi, D., (1986). Effetto del sulodexide su alcuni fattori di rischio metabolici nella macroangiopatia diabetica. Farmaco. Prat., 61, 67-76.
8. Kofoed-Enevoldsen, A., (1995). Heparan sulphate in the pathogenesis of diabetic nephropathy. Diab. Metab. Rev., 11, 137-160.
9. Kverneland, A., Feldt-Rasmussen, B., Vidal, P., et al., (1986). Evidence of changes in renal charge selectivity in patients with type I (insulin-dependent) diabetes mellitus. Diabetologia, 29, 634-639.
10. Mauer, S. M., Steffes, M. W., Ellis, E. N., et al., (1984). Structural-functional relationships in diabetic nephropathy. J. Clin. Invest., 74, 1143-1155.
11. Mazzi, C., Mainini, E., Morandi, G., et al., (1984). Effetto del sulodexide sui fattori determinanti della micro-e macro-angiopatia diabetica: studio clinico-metabolico. Farmaci, 8, 439-448.
12. Myrup, B., Hansen, P. N., Jensen, T., et al., (1995). Effect of low-dose heparin on urinary albumin excretion in insulin-dependent diabetes mellitus. Lancet, 345, 421-422.
13. Nathan, D. M., (1993). Long-term complications of diabetes mellitus. N. Engl. J. Med., 328, 1676-1685.
14. Negrini, F., Botrugno, A., and Gerali, P., (1986). A study of the clinical, antithrombotic and hemorrheologic activity of sulodexide in patients with diabetic vasculopathy. Farm. Ter., 3, 130-134.
15. Osterby, R., (1985). Early phases in the development of diabetic glomerulopathy: a quantitative electron microscopic study. Acta Med. Scand., 574, Suppl, 3-82.
16. Palmieri, G. C., Nazzari, M., Ambrosi, G., et al., (1984). Sulodexide in the treatment of peripheral arterial disease. Clin. Trials. J., 21, 411-427.
17. Parodi, F., and Cataldi, L., (1985). Il sulodexide nelle vasculopatie arteriosclerotiche periferiche dei diabetici. Giorn. Gerontol., 33, 237-242.
18. Piva, I., Lora, L., Basso, A., et al., (1985). Studio controllato dell'effetto del sulodexide nella macroangiopatia diabetica periferica. Giorn. Clin. Med., 66, 37-45.
19. Selby, J. V., FitzSimmons, S. C., Newman, J. M., et al., (1990). The natural history and epidemiology of diabetic nephropathy: implications for prevention and control. JAMA, 236, 1954-1960.
20. Solini, A., Carraro, A., Barzon, I., et al., (1994). Therapy with glycosaminoglycans lowers albumin excretion rate in non-insulin-dependent diabetic patients with macroalbuminuria. Diab. Nutr. Metab., 7, 304-307.
21. Tamsma, J. T., Van der Born, J., Bruijn, J. A., et al., (1994). Expression of glomerular extracellular matrix components in human diabetic nephropathy: decrease of heparan sulphate in the glomerula basement membrane. Diabetologia, 37, 313-320.
22. Velussi, M., Cernigoi, A. M., Dapas, F., et al., (1996). Glycosaminoglycans oral therapy reduces microalbuminuria, blood fibrinogen levels and limb arteriopathy clinical signs in patients with non-insulin dependent diabetes mellitus. Diab. Nutr. Metab., 9, 53-58.
23. Vernier, R. L., Steffes, M.W., Sisson-Ross, S., et al., (1992). Heparan sulfate proteoglycan in the glomerular basement membrane in type I diabetes mellitus. Kidney Int., 41, 1070-1080.